Intravitreal Ranibizumab and/or Dexamethasone Implant for Macular Edema Secondary to Retinal Vein Occlusion

Autor:	Sylvia Nghiem-Buffet, Gabriel Quentel, Marc Buffet, Typhaine Grenet, Sandrine Ayrault, Franck Fajnkuchen, Corinne Delahaye-Mazza, Anna Le Gloahec-Lorcy, Salomon Y. Cohen
Rok vydání:	2014
Předmět:	Male medicine.medical_specialty Time Factors Retinal Vein genetic structures Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized Dexamethasone Macular Edema Central retinal vein occlusion Ranibizumab Ophthalmology Retinal Vein Occlusion Occlusion medicine Humans Glucocorticoids Macular edema Aged Retrospective Studies Drug Implants business.industry General Medicine medicine.disease eye diseases Sensory Systems Vitreous Body Treatment Outcome Intravitreal Injections Branch retinal vein occlusion Female sense organs Implant business Tomography Optical Coherence Follow-Up Studies medicine.drug
Zdroj:	Ophthalmologica. 232:216-222
ISSN:	1423-0267 0030-3755
Popis:	Purpose: To investigate the outcome of intravitreal ranibizumab and/or dexamethasone implant treatment for treatment of macular edema (ME) secondary to central or branch retinal vein occlusion (CRVO or BRVO) in a clinical setting. Methods: Retrospective analysis of consecutive patients followed for at least 6 months. Data recorded included the type of occlusion, initial and final visual acuity, and number of injections. Results: Sixty-five patients were included, 26 had CRVO and 39 BRVO. Mean (±SD) follow-up duration was 16 (±7.7) months. Twenty-four (36.9%) patients received ranibizumab in monotherapy, 19 patients (29.3%) dexamethasone in monotherapy, and 22 patients (33.8%) received successively both treatments. In dexamethasone-treated patients, mean (±SD) visual acuity gain was 5.8 ± 10.7 letters for BRVO and 16.8 ± 15.6 letters for CRVO. In ranibizumab-treated patients, mean (±SD) visual acuity gain was 9.2 ± 10 letters for BRVO and 18.2 ± 20.5 letters for CRVO. Conclusion: Both intravitreal ranibizumab and dexamethasone intravitreal implant could be used as first-line therapy for patients with ME secondary to retinal vein occlusion.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e523d9e695f367fe921fcef27599d7ef https://doi.org/10.1159/000365639 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.